Dr. Lara A. Dunn, MD
- Medicare services, 2024
- 594
- Medicare patients, 2024
- 164
- Part D claims, 2024
- 648
- Publications
- 66
- Clinical trials
- 7
- Practice address
- 1275 York Avenue, New York, NY 10065
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Dunn's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Lara A. Dunn is a medical oncologist in New York, New York
Dr. Dunn practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.
Dr. Dunn's NPI, 1740416197, was assigned on May 29, 2009. Dr. Dunn graduated from Perelman School of Medicine - Philadelphia in 2009. Dr. Dunn holds New York license 262228.
- NPI
- 1740416197NPI Registry (opens in a new tab)
- Medicare PAC ID
- 6800037326
- NPI enumeration date
- May 29, 2009
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 43
- Medical school graduation
- 2009
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Lara A. Dunn practices at Memorial Sloan Kettering Cancer Center in New York, New York
Dr. Dunn's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.
- Memorial Sloan Kettering Cancer Center1275 York Avenue, New York, NY 10065
Source: Dmand AI Affiliation Data
Dr. Lara A. Dunn is affiliated with 2 sites of care and 2 medical groups
Dr. Dunn's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Dunn to 1 more home health agency and 1 medical group, each named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Lara A. Dunn's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dunn practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Memorial Sloan Kettering Cancer Center | Available with a free account |
| +1 more site and 1 medical group | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Memorial Sloan Kettering Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Lara A. Dunn is one of 458 medical oncologists in New York
Medical oncology is Dr. Dunn's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dunn is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Dunn's licenses on file in 3 states: New York, Florida and New Jersey.
Specialties and state licenses
- Medical oncology, New YorkPrimary
- Florida license
- New Jersey license
Clinical focus
Dmand AI lists chronic leukemia and lymphoma among the conditions Dr. Dunn treats.
Medical oncologists near Dr. Dunn
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Lara A. Dunn billed Medicare for 594 services in 2024
CMS data shows 594 Medicare services from Dr. Dunn across 4 procedure codes in 2024, for 164 Medicare patients. Medicare paid $63,009 for them. Every service was in an office.
Dr. Dunn's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 5002024: 59419%
- Other services
- 2023: 322024: 0100%
Dr. Dunn compared with the New York median for medical oncologists, 2024
- Dr. Dunn
- New York median
- Medicare services
- 594vs 34075% above
- Medicare patients
- 164vs 11246% above
- Part D claims
- 439vs 1303.4 times
Medians across 421 medical oncologists in New York with Dmand AI profiles that report each measure.
Dr. Dunn's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Dunn?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Dunn and other medical oncologists in New York.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Lara A. Dunn treated 164 Medicare patients in 2024, average age 74
CMS counts 164 Medicare patients who saw Dr. Dunn in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Dunn's median patient age at 72, with 26% women.
Dr. Dunn's Medicare patients by age, 2024
Dr. Dunn's Medicare patients by sex, 2024
- Women4829%
- Men11671%
Chronic conditions among Dr. Dunn's Medicare patients, 2024
- High cholesterol75%
- High blood pressure73%
- Arthritis45%
- Anxiety35%
- Diabetes32%
- Ischemic heart disease30%
- Cancer27%
- Chronic kidney disease23%
Share of Medicare patients with each condition. A patient can have several.
Dr. Dunn's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 72
Patient panel by sex, all payers
- Women26%
- Men72%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Lara A. Dunn wrote 648 Medicare Part D claims in 2024
In 2024, Dr. Dunn wrote 648 Medicare Part D claims for 99 patients. 88% of them were for generic drugs. CMS names the drug for 439 of them, across 17 drugs with 11 or more claims each, at $10,450 in total drug cost. In 2023, CMS named 311 claims across 13 drugs.
Dr. Dunn's Part D claims by kind of drug, 2024
- Generic573 claims88%
- Brand-name and other75 claims12%
Dr. Dunn's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Dunn's Part D claims, 2024
- Opioids26%168 of 648 claims
- Antibiotics4%27 of 648 claims
- Antipsychotics, patients 65 and over3%17 of 648 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 3112024: 43941%
Drugs named by CMS: 17 in 2024, 13 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Lara A. Dunn scored 76 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Dunn for performance year 2024, reported as part of a group. Dr. Dunn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dunn as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Dr. Dunn's MIPS scores, performance year 2024
- 76of 100Final score
- 60.6of 100Quality
- 40of 100Improvement Activities
- 74of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Lara A. Dunn has 66 publications on record
Dmand AI links 66 papers to Dr. Dunn, published from 2015 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Squamous Cell Carcinoma of Head and Neck. Dr. Dunn has published most often in Oral Oncol. Dr. Dunn's most frequent co-authors are Nadeem Riaz, MD, David G. Pfister, MD and Yao Yu, MD.
Dr. Dunn's papers by year, 2016 to 2025
Topics Dr. Dunn writes about most
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Antineoplastic Agents
- Chemoradiotherapy
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma
- Oropharyngeal Neoplasms
Dr. Dunn's most frequent co-authors
Recent publications by Dr. Dunn
See who Dr. Dunn researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Dunn works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Lara A. Dunn has worked on 7 clinical trials
Dmand AI links Dr. Dunn to 7 clinical trials, 4 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck and Adenocarcinoma, Sebaceous. Memorial Sloan Kettering Cancer Center sponsors the most, 4. Open Payments lists research payments to Dr. Dunn that name 1 trial.
Clinical trials with Dr. Dunn by phase
- 3Phase 1: 3 trials
- 4Phase 2: 4 trials
- NonePhase 3: no trials
- NonePhase 4: no trials
Conditions in Dr. Dunn's trials
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Adenocarcinoma, Sebaceous
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
Investigators on the most trials with Dr. Dunn
- Ivy Elizabeth Abraham1 shared trial
- Donald J. Annino, DMD, MD1 shared trial
- Christopher Andrew Barker, MD1 shared trial
Recent clinical trials with Dr. Dunn
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma (opens in a new tab)
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (opens in a new tab)
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer (opens in a new tab)
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer (opens in a new tab)
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Lara A. Dunn received $46,129 in industry payments from 2017 to 2025
CMS Open Payments shows 64 general payments to Dr. Dunn from 5 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 85% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $38,261. It also lists 89 research payments totaling $11,444 from 2018 to 2024, naming 1 clinical trial.
General payments to Dr. Dunn by program year, 2017 to 2025
General payments to Dr. Dunn by kind, 2017 to 2025
- Consulting fees$39,14785%
- Travel and lodging$5,55812%
- Food and beverage$1,4243%
Companies that paid Dr. Dunn the most, 2017 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Lara A. Dunn graduated from Perelman School of Medicine - Philadelphia
Dr. Dunn graduated from Perelman School of Medicine - Philadelphia in 2009. Dr. Dunn is a member of ASCO.
- Medical school
- Board certified in medical oncology
Source: Dmand AI Professional Profile Data
Dr. Lara A. Dunn accepts plans from 13 insurance carriers
Dr. Dunn is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.
- Aetna
- Blue Cross Blue Shield of Michigan
- Excellus BlueCross BlueShield
- United Healthcare
- Blue Cross Blue Shield of Massachusetts
- HCSC
- MVP Health Care
- Aspirus Health Plan
- +5 more carriersWith a free account
Plan types Dr. Dunn accepts, by number of carriers
- PPO9
- Medicare7
- EPO4
- HMO4
- POS4
- Medicaid1
Source: Dmand AI Insurance Network Data
Sources for Dr. Lara A. Dunn's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Lara A. Dunn
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Lara A. Dunn's NPI number?
Dr. Lara A. Dunn's NPI number is 1740416197. It was assigned on May 29, 2009, and it is active in the NPI Registry.
What kind of doctor is Dr. Lara A. Dunn?
Dr. Lara A. Dunn is a medical oncologist in New York, New York. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Lara A. Dunn practice?
Dr. Dunn practices at 1275 York Avenue, New York, NY 10065. Dr. Dunn's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Dunn to 1 home health agency and 1 medical group.
What is Dr. Lara A. Dunn's medical license number?
Dr. Dunn holds New York license 262228, one of the licenses on file in 3 states.
Which states has Dr. Lara A. Dunn been licensed in?
Dmand AI has state licenses on file for Dr. Dunn in New York (2011 to 2026), Florida (since 2021) and New Jersey (2019 to 2025).
Which hospitals is Dr. Lara A. Dunn affiliated with?
Dr. Dunn practices at Memorial Sloan Kettering Cancer Center in New York, New York.
What medical group is Dr. Lara A. Dunn part of?
Dr. Dunn is linked to Memorial Sloan Kettering Cancer Center. Dmand AI links Dr. Dunn to 1 more medical group.
Does Dr. Lara A. Dunn accept Medicare?
Yes. CMS data shows Dr. Dunn billed Medicare for 594 services in 2024, and Dr. Dunn accepts Medicare assignment.
Does Dr. Lara A. Dunn offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Dunn as offering telehealth services.
What is Dr. Lara A. Dunn's MIPS score?
Dr. Dunn's MIPS final score for performance year 2024 is 76 out of 100, reported as part of a group.
Show 10 more questionsShow fewer questions
How many Medicare patients does Dr. Lara A. Dunn see?
CMS counts 164 Medicare patients who saw Dr. Dunn in 2024, with an average age of 74.
Is Dr. Lara A. Dunn board certified?
Yes. Dr. Dunn is board certified in medical oncology by the American Board of Internal Medicine.
What services does Dr. Lara A. Dunn bill to Medicare?
In 2024, Dr. Dunn's most billed Medicare services were office visit, established patient (99214), office visit, established patient (99215) and office visit, new patient (99205).
Where did Dr. Lara A. Dunn go to medical school?
Dr. Dunn graduated from Perelman School of Medicine - Philadelphia in 2009.
What drugs does Dr. Lara A. Dunn prescribe most?
In 2024 Medicare Part D data, Dr. Dunn's most prescribed drugs by claims were Fentanyl, Oxycodone HCl and Levothyroxine Sodium.
Has Dr. Lara A. Dunn received payments from drug or device companies?
CMS Open Payments shows $46,129 in general payments to Dr. Dunn from 5 companies from 2017 to 2025. The largest total came from Regeneron Pharmaceuticals, Inc.
How long has Dr. Lara A. Dunn been practicing?
Dr. Dunn graduated from medical school in 2009, 17 years ago.
Does Dr. Lara A. Dunn do research?
Dmand AI links 66 publications to Dr. Dunn, published from 2015 to 2025. Dr. Dunn has worked on 7 clinical trials.
Who does Dr. Lara A. Dunn publish with?
Dr. Dunn's most frequent co-authors are Nadeem Riaz, MD (26 shared papers), David G. Pfister, MD (25 shared papers) and Yao Yu, MD (23 shared papers).
What insurance does Dr. Lara A. Dunn accept?
Dr. Dunn is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.
Selling to medical oncology practices?
See medical oncologists in New York by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card